KR102259003B1 - Composition for prevention or treatment of atopic dermatitis with Sargentodoxa cuneata - Google Patents
Composition for prevention or treatment of atopic dermatitis with Sargentodoxa cuneata Download PDFInfo
- Publication number
- KR102259003B1 KR102259003B1 KR1020190116264A KR20190116264A KR102259003B1 KR 102259003 B1 KR102259003 B1 KR 102259003B1 KR 1020190116264 A KR1020190116264 A KR 1020190116264A KR 20190116264 A KR20190116264 A KR 20190116264A KR 102259003 B1 KR102259003 B1 KR 102259003B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- present
- cells
- composition
- skin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 206010012438 Dermatitis atopic Diseases 0.000 title abstract description 11
- 201000008937 atopic dermatitis Diseases 0.000 title abstract description 11
- 230000002265 prevention Effects 0.000 title description 3
- 241000501113 Sargentodoxa cuneata Species 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 61
- 210000004369 blood Anatomy 0.000 claims abstract description 24
- 239000008280 blood Substances 0.000 claims abstract description 24
- 239000002537 cosmetic Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 238000000605 extraction Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- 230000008929 regeneration Effects 0.000 claims description 5
- 238000011069 regeneration method Methods 0.000 claims description 5
- 210000004927 skin cell Anatomy 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 4
- 230000037319 collagen production Effects 0.000 claims description 3
- 206010003645 Atopy Diseases 0.000 abstract description 24
- 210000004027 cell Anatomy 0.000 description 26
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 238000009472 formulation Methods 0.000 description 16
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 14
- 230000028327 secretion Effects 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 14
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 11
- 229960001340 histamine Drugs 0.000 description 10
- -1 ELIXIRS Substances 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 239000000306 component Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000344 soap Substances 0.000 description 6
- 229960005322 streptomycin Drugs 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229940028885 interleukin-4 Drugs 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 4
- 239000004017 serum-free culture medium Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 241000122938 Strongylus vulgaris Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000003918 blood extract Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000037307 sensitive skin Effects 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 240000006891 Artemisia vulgaris Species 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 235000021319 Palmitoleic acid Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 240000006054 Agastache cana Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241001632576 Hyacinthus Species 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000219098 Parthenocissus Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 240000000275 Persicaria hydropiper Species 0.000 description 1
- 235000017337 Persicaria hydropiper Nutrition 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- 241001106462 Ulmus Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 235000015122 lemonade Nutrition 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Chemical class 0.000 description 1
- 239000011782 vitamin Chemical class 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 대혈등 추출물을 함유하는 아토피 피부염 개선 및 치료, 예방용 조성물에 관한 것으로, 아토피 피부 개선, 예방 또는 치료 효과가 우수하다.The present invention relates to a composition for improving, treating, and preventing atopic dermatitis containing an extract of such a blood, and is excellent in improving, preventing or treating atopic skin.
Description
본 발명은 대혈등(大血藤) 추출물을 함유하는 아토피 피부염 개선 및 치료, 예방용 조성물에 관한 것이다.The present invention relates to a composition for improving, treating, and preventing atopic dermatitis containing an extract of Daehyeol, etc. (大血藤).
아토피는 심한 가려움증을 가지는 재발성 만성피부염으로, 어린이의 약 10~15%가 아토피성 피부염을 가지고 있으며, 이중 90%는 5년 내에 자연적으로 호전되는 것으로 보고되어 있다. 아토피는 성인기에 대체로 호전되어 약 30~40%는 외관상으로 피부염이 재발되지 않으나, 나머지는 성인이 되어서도 피부 건조, 자극성 물질에 의한 피부자극, 주부습진 등의 피부염으로 어려움을 겪는 것으로 알려져 있다. 민감성 피부의 경우 수분 보유력 및 회복력이 낮고, 피부 각질화, 가려움증 등이 나타나기 쉽기 때문에 아토피성 피부염이 유발될 확률이 높다.Atopic dermatitis is a recurrent chronic dermatitis with severe itching, and about 10 to 15% of children have atopic dermatitis, and 90% of them are reported to improve spontaneously within 5 years. It is known that atopic dermatitis generally improves in adulthood, and dermatitis does not recur in about 30-40% of them, but the rest suffer from dermatitis such as dry skin, skin irritation by irritants, and housewife eczema even as adults. In the case of sensitive skin, moisture retention and recovery are low, and skin keratinization and itching are easy to occur, so atopic dermatitis is highly likely to occur.
아토피의 정확한 병리 생리는 아직까지 완전히 이해되고 있지 않지만 유전적 소인과 함께 면역학적, 비면역학적 기전이 관여한다고 보고 있다. 아토피의 대부분을 차지하는 외인성 아토피는 IgE와 연관된 면역 기전에 의해 발생되는데 특정 알레르겐(allergen)에 대한 즉시형 면역 반응보다는 T세포 이상에 의한 지연성 면역 반응이 관여한다는 보고들이 많다. 또한,요즘은 B세포로부터 IgE의 생성을 유도하는 IL-4 등 Th2 관련 사이토카인(cytokie)들이 아토피의 원인이라고 보고되고 있다(JS Kang et al., Ihhibition of atopic dermatitis by topical application of silymarin in NC/Nga mice. intl immunopharm. (2008) 8. 1475-1480).Although the exact pathophysiology of atopy is not yet fully understood, it is believed that immunological and non-immunological mechanisms are involved along with genetic predisposition. Exogenous atopy, which accounts for most of atopy, is caused by an immune mechanism related to IgE, and there are many reports that a delayed immune response caused by T cell abnormality rather than an immediate immune response to a specific allergen is involved. In addition, these days, Th2-related cytokines such as IL-4 that induce the production of IgE from B cells are reported to be the cause of atopy (JS Kang et al., Ihhibition of atopic dermatitis by topical application of silymarin in NC). /Nga mice. intl immunopharm. (2008) 8. 1475-1480).
이러한 아토피를 치료하기 위하여, 종래 세라마이드, 리놀레산, 식물유 또는 광물성 오일 등의 성분들, 하이드로코티손(hydrocortisone) 등의 스테로이드(steroid) 제제 또는 이들에 항균 및 항염 기능을 강화한 물질, 자외선 요법을 통한 DNA 합성 억제게, 세포 과증식 억제제, 염증 및 가려움증 억제제 등이 제안된 바 있다. 그러나, 상기 스테로이드 제제는 표피의 성장억제나 부작용 등의 역효과를 유발할 수 있으며, 우레아 퍼록사이드 등은 피부의 과다 자극을 야기할 수 있고, 항히스타민제 등의 항생물질은 균의 내성(resistance) 및 광과민 등의 부작용을 유발할 가능성이 높은 문제점이 있다. 또한, 장기간 피부에 적용시 모세 혈관 확장증 또는 각질층의 두께 증가 내지 확장을 유발하는 등의 심각한 부작용을 발생시킬 염려가 있으며, 최근 아토피 완화에 많이 쓰이는 감마-리놀레산(한국특허공개 2000-0046633호)은 쉽게 산화되므로 안정성이 열등함과 아울러, 피부 자극성이 비교적 강하여 민감한 피부에는 사용하기 곤란한 등의 문제점이 있다.In order to treat such atopic dermatitis, conventional components such as ceramide, linoleic acid, vegetable oil or mineral oil, steroids such as hydrocortisone, or substances with enhanced antibacterial and anti-inflammatory functions therein, DNA synthesis through UV therapy Inhibitors, inhibitors of cell hyperproliferation, inhibitors of inflammation and pruritus, and the like have been proposed. However, the steroid preparation may cause adverse effects such as growth inhibition or side effects of the epidermis, urea peroxide and the like may cause excessive skin irritation, and antibiotics such as antihistamines may cause bacterial resistance and photosensitivity. There are problems that are highly likely to cause side effects, such as. In addition, when applied to the skin for a long period of time, there is a concern that serious side effects such as telangiectasia or increase or expansion of the stratum corneum may occur. Since it is easily oxidized, stability is inferior, and skin irritation is relatively strong, so it is difficult to use on sensitive skin.
이에 따라 최근에는 아토피에 효과를 갖는 천연물질을 탐색하는데 초점을 맞추고 있다. 대표적으로, 쑥 추출물(대한민국 특허등록 제10-0377262호), 영지버섯, 유근피, 감초, 백봉령, 백지마 및 백년초의 추출물(대한민국 특허등록 제10-0517465호), 달맞이유, 알로에, 목초액, 제비꽃, 대추, 송이버섯, 두릅, 인삼, 녹차, 두충, 복분자, 오미자, 쑥, 포공영, 삼백초, 황기, 하고초, 해송, 황금 및 우슬의 추출물(대한민국 특허등록 제10-0451444호), 청자소엽과 적자소엽의 추출물(대한민국 특허등록 제10-0454752호), 건률, 의이인, 오미자, 길경, 나복자, 맥문동 및 석창포의 추출물(대한민국 특허등록 제10-0483539호), 라벤더, 유칼립투스 및 티트리 오일(대한민국 특허등록 제10-0597997호) 등이 있고, 그 외에도 상기생, 합환피, 창이자, 맥아 등이 효과가 있다고 알려져 있다. 그러나, 상기 천연물질들은 그 효능이 미미하거나, 효과는 있더라도 민감성 피부에 있어서는 알레르기 과민반응을 보여 그 사용이 제한되는 단점이 있었다. 따라서, 종래 알려진 아토피 개선 및 치료제에 비하여 보다 효과가 뛰어나고 안전한 물질을 개발하는 것이 요구되고 있는 실정이다.Accordingly, in recent years, the focus has been on the search for natural substances having an effect on atopy. Representatively, mugwort extract (Korean Patent Registration No. 10-0377262), reishi mushroom, Eugeunpi, licorice, baekbongryeong, white hemp and baeknyeoncho extract (Korea Patent Registration No. 10-0517465), evening primrose oil, aloe, wood vinegar, violet, Extracts of jujube, matsutake mushroom, elm, ginseng, green tea, duchung, bokbunja, omija, mugwort, pogongyeong, sambaekcho, hwanggi, hagograss, sea pine, gold and hyssop (Korea Patent Registration No. 10-0451444), celadon leaflet and red Leaf extract (Korean Patent Registration No. 10-0454752), Geonryul, Uiin, Omija, Gilkyung, Nabokja, Maekmundong and Seokchangpo extracts (Korean Patent Registration No. 10-0483539), Lavender, Eucalyptus and Tea Tree Oil (Korean Patent) Registration No. 10-0597997), etc., and in addition to that, it is known that the above-mentioned saengsaeng, hyacinth skin, Changja, malt, etc. are effective. However, the natural substances have a disadvantage in that their efficacy is insignificant or, although effective, they show allergic hypersensitivity reactions in sensitive skin, limiting their use. Therefore, there is a need to develop a substance that is more effective and safer than conventionally known atopy improvement and therapeutic agents.
본 발명은 아토피 피부 개선 효과가 뛰어난 천연물의 추출물을 발굴하고, 이를 유효성분으로 함유하는 조성물을 개발하여 제공하는 것을 목적으로 한다.An object of the present invention is to discover an extract of a natural product having excellent atopic skin improvement effect, and to develop and provide a composition containing it as an active ingredient.
본 발명은 대혈등 추출물을 함유하는 것을 특징으로 하는 아토피 피부염 예방 및 치료용 약학 조성물을 제공한다.The present invention provides a pharmaceutical composition for the prevention and treatment of atopic dermatitis, characterized in that it contains an extract such as Great Blood.
또한, 본 발명은 대혈등 추출물을 함유하는 것을 특징으로 하는 아토피 피부 개선용 화장료 조성물을 제공한다.In addition, the present invention provides a cosmetic composition for improving atopic skin, characterized in that it contains an extract such as Great Blood.
또한, 본 발명은 대혈등 추출물을 함유하는 것을 특징으로 하는 아토피 피부 개선용 식품 조성물을 제공한다.In addition, the present invention provides a food composition for improving atopic skin, characterized in that it contains an extract such as Great Blood.
본 발명에 있어서, 상기 대혈등 추출물은, 바람직하게는 에탄올을 추출용매로 사용하는 것이 좋다.In the present invention, the extract, such as the Great Blood, preferably uses ethanol as an extraction solvent.
본 발명은 대혈등 추출물을 함유하여 아토피 피부 개선, 예방 또는 치료 효과가 우수한 조성물을 제공한다.The present invention provides a composition excellent in improving, preventing, or treating atopic skin by containing the extract of Daehyeol, etc.
도 1은 대혈등 추출물의 세포독성 실험 결과이다.
도 2는 대혈등 추출물의 염증유발인자인 산화질소 분비 억제 실험 결과이다.
도 3은 대혈등 추출물의 면역글로블린 E 분비 억제 실험 결과이다.
도 4는 대혈등 추출물의 히스타민 분비 억제 실험 결과이다.
도 5는 대혈등 추출물의 콜라겐 합성 실험 결과이다.1 is a result of a cytotoxicity test of extracts such as Daehyeol.
2 is a result of an experiment to suppress the secretion of nitric oxide, which is an inflammation-inducing factor, of extracts such as Dae blood.
3 is a result of an immunoglobulin E secretion suppression experiment of Daehyeol, etc. extract.
4 is a result of the histamine secretion inhibition experiment of the extract of Daehyeol, etc.
5 is a collagen synthesis experiment result of the extract of Daehyeol, etc.
본 발명은 대혈등 추출물을 함유하는 아토피 피부염 예방 및 치료용 약학 조성물을 제공한다. 또한 본 발명은 대혈등 추출물을 함유하는 아토피 피부 개선용 화장료 조성물 및 식품 조성물을 제공한다.The present invention provides a pharmaceutical composition for the prevention and treatment of atopic dermatitis containing the extract, such as Dae blood. In addition, the present invention provides a cosmetic composition and a food composition for improving atopic skin containing an extract such as Great Blood.
본 발명에서 사용하는 대혈등(大血藤, Sargentodoxa cuneata)은 으름덩굴과로, 원기둥 모양이며 약간 구부러진 형태이다. 길이 30~60cm이고 지름은 1~3cm이다. 바깥 면은 회갈색이나 갈색으로 거친 특징이 있다. 자른 면은 적갈색으로 여러 곳에서 안으로 향하여 목부로 끼어들어 방사상의 꽃무늬를 이룬다. 약간의 냄새가 있으며 쓴맛이 나는 특징이 있다. Daehyeoldeung (大血藤, Sargentodoxa cuneata ) used in the present invention is a creeper, a cylindrical shape and a slightly curved shape. It is 30-60 cm long and 1-3 cm in diameter. The outer surface is grayish-brown or brown with rough features. The cut side is reddish-brown in several places and is inserted into the neck to form a radial flower pattern. It has a slight odor and has a bitter taste.
본 발명에 있어서, 상기 대혈등 추출물은 본 발명이 속하는 기술 분야에서 통상적으로 사용되는 다양한 추출 방법을 이용할 수 있다. 예를 들면, 정제수, 탄소수 1-4의 무수 또는 함수 저급 알코올, 프로필렌글리콜, 부틸렌글리콜, 글리세린, 아세톤, 에틸 아세테이트, 클로로포름, 부틸 아세테이트, 디에틸에테르, 디클로로메탄, 헥산 또는 이들의 혼합물로 구성된 군으로부터 선택되는 추출용매를 이용할 수 있다. 바람직하게는 물 또는 유기용매를 가하여 추출하는 것이 좋다.In the present invention, the extracts such as Great Blood may use various extraction methods commonly used in the technical field to which the present invention pertains. For example, purified water, anhydrous or hydrous lower alcohol having 1-4 carbon atoms, propylene glycol, butylene glycol, glycerin, acetone, ethyl acetate, chloroform, butyl acetate, diethyl ether, dichloromethane, hexane or mixtures thereof. An extraction solvent selected from the group may be used. Preferably, water or an organic solvent is added for extraction.
본 발명에 있어서, 상기 대혈등 추출물은 대혈등 전체 건조 중량의 5배 내지 20배를 첨가하는 것이 바람직하고, 전체 건조 중량의 20배를 첨가하는 것이 더욱 바람직하다.In the present invention, it is preferable to add 5 to 20 times the total dry weight of the Great Blood extract, and more preferably 20 times the total dry weight of the Great Blood extract.
본 발명에 있어서, 상기 대혈등 추출물의 추출시 온도는 10℃ 내지 120℃ 인 것이 바람직하며, 더욱 바람직하게는 40℃ 내지 100℃인 것일 수 있다. 상기 추출 시간은 1시간 내지 7시간인 것이 바람직하며, 더욱 바람직하게는 3시간 내지 5시간인 것일 수 있다. 상기 추출물을 제조하는 방법은 열수 추출, 침지 추출, 환류 냉각 추출, 초임계추출, 아임계추출, 고온추출, 고압추출 또는 초음파추출법 등의 추출장치를 이용한 방법 또는 XAD 및 HP-20을 포함한 흡착 수지를 이용하는 방법 등 당업계의 통상적인 추출방법을 사용할 수 있다.In the present invention, the extraction temperature of the extract such as Great Blood may be preferably in the range of 10 °C to 120 °C, more preferably 40 °C to 100 °C. The extraction time may be preferably 1 hour to 7 hours, more preferably 3 hours to 5 hours. The method for preparing the extract is a method using an extraction device such as hot water extraction, immersion extraction, reflux cooling extraction, supercritical extraction, subcritical extraction, high temperature extraction, high pressure extraction or ultrasonic extraction, or an adsorption resin including XAD and HP-20 A conventional extraction method in the art, such as a method using
본 발명의 대혈등 추출물은 아토피에서 관찰되는 산화 질소 분비를 억제하여 항염 효과가 있는 것으로 확인되었으며, 면역글로불린 E(Immunoglobulin E)의 분비를 억제하고, 히스타민(histamine) 분비를 억제하여 아토피 개선 효과가 우수한 것으로 확인되었다. 또한, 본 발명의 대혈등 추출물은 콜라겐 합성 효과가 우수하여 피부세포 재생 효과를 발휘하는 것을 확인하였다. 이에 따라, 본 발명의 대혈등 추출물은 아토피 개선, 예방 또는 치료용 조성물로서 사용될 수 있다.It was confirmed that the extract of the Great Bloodworm of the present invention has an anti-inflammatory effect by suppressing the secretion of nitric oxide observed in atopy, suppressing the secretion of immunoglobulin E (Immunoglobulin E), and suppressing the secretion of histamine, thereby improving atopy. was found to be excellent. In addition, it was confirmed that the extract of the Great Bloodworm of the present invention exhibits a skin cell regeneration effect due to excellent collagen synthesis effect. Accordingly, the extract of the present invention can be used as a composition for improving, preventing or treating atopy.
한편, 본 발명의 약학 조성물은 약제학적으로 허용 가능한 담체, 희석제 또는 부형제를 더욱 포함할 수 있다. 사용가능한 담체, 부형제 또는 희석제로는, 락토즈, 덱스트로즈, 수크로즈, 솔비톨, 만니톨, 자이리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유가 있으며, 이중 선택되는 하나 이상을 사용할 수 있다. 또한, 치료 및 예방제가 약제인 경우 충진제, 항응집제, 윤활제, 습윤제, 향료, 유화제 또는 방부제 등이 추가적으로 포함될 수 있다.On the other hand, the pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier, diluent or excipient. Usable carriers, excipients or diluents include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, There are microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil, and at least one selected from among them may be used. In addition, when the therapeutic and prophylactic agent is a pharmaceutical, a filler, an anti-aggregant, a lubricant, a wetting agent, a fragrance, an emulsifier, or a preservative may be additionally included.
한편, 본 발명의 약학 조성물의 제형은 사용 방법에 따라 바람직한 형태로 제조될 수 있으며, 특히 포유동물에 투여된 후 활성 성분의 신속, 지속 또는 지연된 방출을 제공할 수 있도록 당업계에 공지된 방법을 채택하여 제형화 하는 것이 좋다. 구체적인 제형의 예로는 경고제(PLASTERS), 과립제(GRANULES), 로션제(LOTIONS), 리니멘트제(LINIMENTS), 리모나데제(LEMONADES), 방향수제(AROMATIC WATERS), 산제(POWDERS), 시럽제(SYRUPS), 안연고제(OPHTALMIC OINTMENTS), 액제(LIQUIDS AND SOLUTIONS), 에어로솔제(AEROSOLS), 엑스제(EXTRACTS), 엘릭실제(ELIXIRS), 연고제(OINTMENTS), 유동엑스제(FLUIDEXTRACTS), 유제(EMULSIONS), 현탁제(SUSPESIONS), 전제(DECOCTIONS), 침제(INFUSIONS), 점안제(OPHTHALMIC SOLUTIONS), 정제(TABLETS), 좌제(SUPPOSITIORIES), 주사제(INJECTIONS), 주정제(SPIRITS), 카타플라스마제(CATAPLSMA), 캅셀제(CAPSULES), 크림제(CREAMS), 트로키제(TROCHES), 틴크제(TINCTURES), 파스타제(PASTES), 환제(PILLS), 연질 또는 경질 젤라틴 캅셀 중 선택되는 어느 하나일 수 있다.On the other hand, the dosage form of the pharmaceutical composition of the present invention may be prepared in a desired form according to the method of use, and in particular, methods known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal It is better to adopt and formulate it. Examples of specific formulations include PLASTERS, GRANULES, LOTIONS, LINIMENTS, LEMONADES, AROMATIC WATERS, POWDERS, syrups ( SYRUPS, OPHTALMIC OINTMENTS, LIQUIDS AND SOLUTIONS, AEROSOLS, EXTRACTS, ELIXIRS, OINTMENTS, FLUIDEXTRACTS, EMULSIONS ), suspensions (SUSPESIONS), premises (DECOCTIONS), infusions (INFUSIONS), eye drops (OPHTHALMIC SOLUTIONS), tablets (TABLETS), suppositories (SUPPOSITIORIES), injections (INJECTIONS), alcohol tablets (SPIRITS), CATAPLS ), capsules (CAPSULES), creams (CREAMS), troches (TROCHES), tinctures (TINCTURES), pastas (PASTES), pills (PILLS), it may be any one selected from soft or hard gelatin capsules.
한편, 본 발명의 약학조성물에 있어서, 투여량은 투여방법, 복용자의 연령, 성별 및 체중, 및 질환의 중증도 등을 고려하여 결정하는 것이 좋다. 일 예로, 유효성분인 대혈등 추출물을 기준 (건조중량)으로 하였을 때 1일 0.1 내지 100 mg/kg (체중)으로 1회 이상 투여 가능하다. 다만, 상기의 투여량은 예시하기 위한 일 예에 불과하며, 복용자의 상태와 의사의 처방에 의해 변화될 수 있다.On the other hand, in the pharmaceutical composition of the present invention, the dosage is preferably determined in consideration of the administration method, the age, sex and weight of the user, and the severity of the disease. As an example, based on the active ingredient, such as Daehyeol, etc. extract, as a reference (dry weight), it can be administered at least once at 0.1 to 100 mg/kg (body weight) per day. However, the above dosage is only an example for illustration, and may be changed by the condition of the user and the prescription of the doctor.
한편, 본 발명의 화장료 조성물에 있어서, 상기 대혈등 추출물은, 총 중량 대비 0.001~30 중량% 첨가되는 것이 좋다. 0.001 중량% 미만으로 포함되는 경우에는 본 발명에서 확인한 여러 피부 기능성의 발휘 효과가 미미하고, 30.0 중량%를 초과하는 경우에는 재료 투입량 대비 효율성이 떨어져 경제적이지 못하다.On the other hand, in the cosmetic composition of the present invention, it is preferable that the extract, such as Great Blood, is added in an amount of 0.001 to 30% by weight based on the total weight. When included in an amount of less than 0.001% by weight, the effect of exerting various skin functions confirmed in the present invention is insignificant, and when it exceeds 30.0% by weight, the efficiency is lowered compared to the amount of material input, which is not economical.
한편, 본 발명의 화장료 조성물은, 일 예로, 용액, 현탁액, 유탁액, 페이스트, 화장수, 젤, 수용성 리퀴드, 크림, 에센스, 계면활성제-함유 클렌징, 오일, 수중유(O/W)형 및 유중수(W/O)형 중 선택되는 어느 하나의 기초 화장료 제형; 스킨; 로션; 아이크림; 수딩젤; 연고; 마스크팩용 제형; 바디워시용 제형; 필링젤; 수중유형 및 유중수형 메이크업베이스; 파운데이션; 스킨커버; 립스틱, 립그로스, 페이스파우더, 투웨이케익, 아이새도, 치크칼라 및 아이브로우 펜슬류 중 선택되는 어느 하나의 색조화장료 제형; 두피용 제형; 중에서 선택되는 어느 하나인 것일 수 있다.On the other hand, the cosmetic composition of the present invention, for example, solutions, suspensions, emulsions, pastes, lotions, gels, water-soluble liquids, creams, essences, surfactant-containing cleansing, oil, oil-in-water (O/W) type and oil Any one of the basic cosmetic formulations selected from heavy water (W / O) type; skin; Lotion; eye cream; soothing gel; Ointment; formulations for mask packs; formulations for body wash; peeling gel; Oil-in-water and water-in-oil makeup base; foundation; skin cover; Any one color cosmetic formulation selected from lipstick, lip gloss, face powder, two-way cake, eye shadow, cheek color and eyebrow pencil; formulations for the scalp; It may be any one selected from among.
또한, 본 발명의 화장료 조성물은 화장 분야에서 통상적으로 사용되는 보조제 예컨대 친수성 또는 친유성 활성제, 보존제, 항산화제, 용매, 방향제, 충전제, 차단제, 안료, 흡취제, 염료 등을 함유할 수 있다. 이들 다양한 보조제의 양은 당해 분야에서 통상적으로 사용되는 양이며, 예컨대 조성물 총 중량에 대해 0.001 내지 30 중량% 이다. 다만, 어떠한 경우라도 보조제 및 그 비율은 본 발명에 따른 화장료 조성물의 바람직한 성질에 악영향을 미치지 않도록 선택될 것이다.In addition, the cosmetic composition of the present invention may contain adjuvants commonly used in the cosmetic field, such as hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, fragrances, fillers, blockers, pigments, deodorants, dyes, and the like. The amount of these various adjuvants is an amount conventionally used in the art, for example, 0.001 to 30% by weight relative to the total weight of the composition. However, in any case, the auxiliary agent and its ratio will be selected so as not to adversely affect the desirable properties of the cosmetic composition according to the present invention.
한편, 본 발명의 화장료 조성물에 있어서, 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라가칸트, 셀룰로오스 유도체, 폴리에틸렌글리콜, 실리콘, 벤토나이트, 실라카, 탈크 또는 산화아연 등이 이용될 수 있다.On the other hand, in the cosmetic composition of the present invention, when the formulation is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica as a carrier component , talc or zinc oxide may be used.
또한, 본 발명의 화장료 조성물에 있어서, 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 일례로 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤조에이트, 프로필렌글리콜, 1,3-부틸렌글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌글리콜 또는 소리비탄의 지방산 에스테르가 이용될 수 있다.In addition, in the cosmetic composition of the present invention, when the formulation is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, Benzoate, propylene glycol, 1,3-butylene glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan may be used.
또한 본 발명의 화장료 조성물에 있어서, 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라가칸트 등이 이용될 수 있다.In addition, in the cosmetic composition of the present invention, when the formulation is a suspension, a liquid diluent such as water, ethanol or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester as a carrier component; The same suspending agent, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth and the like can be used.
한편, 본 발명의 화장료 조성물에 있어서, 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.On the other hand, in the cosmetic composition of the present invention, when the formulation is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, in the case of a spray, additionally propellants such as chlorofluorohydrocarbons, propane/butane or dimethyl ether.
한편, 본 발명의 화장료 조성물에 있어서, 제형이 계면활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.On the other hand, in the cosmetic composition of the present invention, when the formulation is surfactant-containing cleansing, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, sarcosinate, Fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester and the like can be used.
또한, 본 발명의 화장료 조성물에 있어서, 계면활성제 함유 클렌징 제형 또는 계면활성제 비함유 클렌징 제형 또는 비누일 경우에는, 피부에 도포한 후 닦아내거나 떼거나 물로 씻어낼 수도 있다. 일례로, 상기 비누는 액상비누, 가루비누, 고형비누 및 오일비누이며, 상기 계면활성제 함유 클렌징 제형은 클렌징 폼, 클렌징 워터, 클렌징 수건 및 클렌징 팩이며, 상기 계면활성제 비함유 클렌징 제형은 클렌징크림, 클렌징 로션, 클렌징 워터 및 클렌징 젤이며, 이에 한정되는 것은 아니다.In addition, in the cosmetic composition of the present invention, in the case of a surfactant-containing cleansing formulation or a surfactant-free cleansing formulation or soap, it may be applied to the skin and then wiped off, removed, or washed off with water. For example, the soap is liquid soap, powder soap, solid soap, and oil soap, the surfactant-containing cleansing formulation is a cleansing foam, cleansing water, cleansing towel and cleansing pack, and the surfactant-free cleansing formulation is a cleansing cream, cleansing lotions, cleansing waters and cleansing gels, but not limited thereto.
또한, 본 발명의 화장료 조성물은 본 발명 이외의 다른 화장료 조성물과 중복하여 사용할 수 있다. 또한 본 발명에 따른 화장료 조성물은 통상적인 사용방법에 따라 사용될 수 있으며, 사용자의 피부 상태 또는 취향에 따라 그 사용횟수를 달리할 수 있다.In addition, the cosmetic composition of the present invention can be used overlapping with other cosmetic compositions other than the present invention. In addition, the cosmetic composition according to the present invention can be used according to a conventional method of use, and the number of times of use can be varied according to the skin condition or taste of the user.
한편, 본 발명의 대혈등 추출물을 함유하는 약학 조성물 또는 화장료 조성물은 바람직하게는 나노리포좀 제형으로 만들어질 수 있다. 나노리포좀은 통상적인 리포좀의 형태를 갖는 것으로 평균 입자 지름이 1~100nm인 리포좀인 것이 바람직하며, 더욱 바람직하게는 30~70nm인 것이 좋다. 상기 리포좀은 수용성 머리와 불용성의 꼬리를 가진 양친매성 분자로 구성된 입자의 상호 자발적인 결합 및 정렬된 콜로이드 입자로, 세포막과 유사한 이중막 구조를 가지며, 이를 함유한 조성물은 피부 흡수력이 더욱 증진되어 아토피 피부 완화 효과가 우수하다.On the other hand, the pharmaceutical composition or cosmetic composition containing the extract of the present invention may be preferably made in a nanoliposome formulation. Nanoliposomes are preferably in the form of conventional liposomes and have an average particle diameter of 1 to 100 nm, more preferably 30 to 70 nm. The liposome is a colloidal particle aligned and spontaneous binding of particles composed of an amphipathic molecule having a water-soluble head and an insoluble tail, and has a double membrane structure similar to a cell membrane. The relief effect is excellent.
본 발명의 나노리포좀은 C12-22 알킬 체인의 포화 또는 불포화 지방산 및 세포간 지질을 포함한다. 본 발명의 나노 리포좀의 제조에 이용되는 C12-22 알킬 체인의 포화 또는 불포화 지방산은, 바람직하게는 라우린산, 미리스트산, 팔미트산, 스테아린산, 올레인산, 리놀레산 및 팔미트올레인산을 포함하며, 더욱 바람직하게는 스테아린산, 팔미트올레인산 및 이의 혼합물로 구성된 군으로부터 선택되는 어느 하나일 수 있다. 상기 나노 리포좀은 피부 외용제 총 중량에 대하여 0.05~5.0 중량%로 함유되는 것이 바람직하나, 더욱 바람직하게는 0.1~.0 중량% 함유되는 것이 좋다. 나노리포좀에 함유되는 대혈등 추출물의 함량은 나노리포좀의 총 중량에 대해서 1.0~20.0 중량%일 수 있으며, 더욱 바람직하게는 3.0~12.0 중량% 함유되는 것이 좋다.The nanoliposomes of the present invention include saturated or unsaturated fatty acids and intercellular lipids of C 12-22 alkyl chains. Saturated or unsaturated fatty acid of C 12-22 alkyl chain used in the preparation of the nanoliposome of the present invention preferably includes lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid and palmitoleic acid. , More preferably, it may be any one selected from the group consisting of stearic acid, palmitoleic acid, and mixtures thereof. The nano-liposome is preferably contained in an amount of 0.05 to 5.0% by weight based on the total weight of the external preparation for skin, more preferably 0.1 to .0% by weight. The content of the extracts such as Great Blood contained in the nanoliposome may be 1.0 to 20.0% by weight based on the total weight of the nanoliposome, more preferably 3.0 to 12.0% by weight.
한편, 본 발명의 식품 조성물은 일 예로 육류, 곡류, 카페인 음료, 일반음료, 초콜렛, 빵류, 스넥류, 과자류, 피자, 젤리, 면류, 껌류, 아이스크림류, 알코올성 음료, 술, 비타민 복합제 및 그 밖의 건강보조식품류 중 선택되는 어느 하나일 수 있으며, 반드시 이에 한정되는 것은 아니다.On the other hand, the food composition of the present invention is, for example, meat, grains, caffeinated beverages, general drinks, chocolate, breads, snacks, confectionery, pizza, jelly, noodles, gums, ice cream, alcoholic beverages, alcohol, vitamin complexes and other health It may be any one selected from supplements, but is not necessarily limited thereto.
한편, 본 발명에서 '유효성분으로 함유하는 것'의 의미는 본 발명에서 요구하는 아토피 피부의 개선, 치료, 예방의 효과가 본 발명의 성분인 대혈등 추출물로부터 발생함을 의미하고, 그 외에 다른 성분을 보조성분으로 포함할 수 있음을 의미한다.On the other hand, in the present invention, the meaning of 'containing as an active ingredient' means that the effect of improving, treating, and preventing atopic skin required in the present invention is generated from the extract, such as large blood, which is a component of the present invention, and other It means that the component may be included as an auxiliary component.
이하, 본 발명에 대해 하기 실시예 및 실험예에서 더욱 상세히 설명하고자 한다. 다만, 본 발명의 권리범위가 하기 실시예 및 실험예에만 한정되는 것은 아니고, 이와 등가의 기술적 사상의 변형까지를 모두 포함한다.Hereinafter, the present invention will be described in more detail in the following Examples and Experimental Examples. However, the scope of the present invention is not limited only to the following examples and experimental examples, and includes all modifications of the technical idea equivalent thereto.
[실시예 1 : 대혈등 추출물의 제조][Example 1: Preparation of extracts from Great Blood, etc.]
대혈등(大血藤)의 덩굴줄기를 정선하여 약전 통칙 중 절도에 따라 조절(4750 ㎛)로 한 뒤, 대혈등 분말 100g에 20배의 70 %(v/v) 에탄올을 넣어 침지하고, 80℃에서 3시간 추출한 후 농축 건조하여 대혈등 추출물을 제조하였다.After selecting the vines of Daehyeoldang (大血藤) and adjusting it (4750 ㎛) according to the moderation in the pharmacopoeia general rule, put 20 times 70% (v/v) ethanol in 100g of Daehyeoldang powder and immerse, 80 After extracting at ℃ for 3 hours, the extract was concentrated to dryness to prepare an extract from dae blood.
[실험예 1 : 대혈등 추출물의 세포독성 측정][Experimental Example 1: Measurement of cytotoxicity of extracts such as Great Blood]
본 실험예에서는 시험관 내(in vito)에서 본 발명에 따른 혼합 추출물의 아토피 개선 및 치료의 효능을 확인하기에 앞서, 세포에 대한 독성이 없으며 최적의 효과를 낼 수 있는 적합한 농도를 결정하기 위해 세포독성 검사를 하였다.In this experimental example, before confirming the efficacy of the atopic improvement and treatment of the mixed extract according to the present invention in vitro, there is no toxicity to the cells, and in order to determine a suitable concentration that can produce the optimal effect Toxicity was tested.
MTT assay는 살아있는 세포 내의 미토콘드리아 탈수소효소에 의해 테트라졸리움(tetrazolium) 염이 포르마잔(formazan)색소로 변환되는 원리를 이용한다. 배지에 첨가한 테트라졸리움 염은 미토콘드리아의 호흡사슬에 존재하며 생존세포에만 활성이 있는 숙신산염 테트라졸리움 환원효소(succinate-tetrazolium-reductase)에 의해 포르마잔 색소로 변환한다. 살아있는 세포수가 증가하면 시료 중의 미토콘드리아 탈수소효소의 전체의 활성이 증가하여 이 효소활성의 증가가 포르마잔 색소의 생성증가를 유도하기 때문에 포르마잔 색소와 배지 중에서 대사활성이 있는 세포의 수는 직선적인 상관관계를 나타내게 된다. 즉, 농도가 높을수록 살아있는 세포수가 많다는 것을 확인할 수 있다.MTT assay uses the principle that tetrazolium salt is converted into formazan pigment by mitochondrial dehydrogenase in living cells. The tetrazolium salt added to the medium is converted into formazan pigment by succinate-tetrazolium-reductase, which exists in the mitochondrial respiratory chain and is active only in living cells. When the number of living cells increases, the overall activity of mitochondrial dehydrogenase in the sample increases, and since the increase in this enzyme activity induces an increase in the production of formazan pigment, the number of metabolically active cells in the formazan pigment and the medium is linearly correlated. will show the relationship. That is, it can be confirmed that the higher the concentration, the greater the number of living cells.
(1) 대식세포주인 RAW 264.7 배양(1) Macrophage cell line RAW 264.7 culture
쥐의 대식세포주인 RAW 264.7 세포는 10% 비활성화 소태아혈청(inactivated fetal bovine serum, GIBCO)과 1% 페니실린·스트렙토마이신(penicillin·streptomycin)이 포함된 DMEM(Dul-becco's Modified Eagle's Medicum)을 배양액으로 하여 37℃에서 5% CO2 조건으로 배양하였다.RAW 264.7 cells, a mouse macrophage cell line, were treated with DMEM (Dul-becco's Modified Eagle's Medicum) containing 10% inactivated fetal bovine serum (GIBCO) and 1% penicillin streptomycin as a culture medium. and incubated at 37° C. under 5% CO 2 conditions.
(2) 세포독성 실험(2) Cytotoxicity test
RAW 264.7 세포를 96 웰 플레이트(well plate)에 웰(well) 당 1×104개로 분주하고 24시간 배양한 후, 10, 50 및 100 ㎍/㎖ 농도로 상기 실시예 1의 대혈등 추출물을 처리하여 48시간동안 배양하였다. 배양액을 흡입하여 제거한 다음 PBS로 1회 세척하고, MTT 용액을 0.5㎎/㎖의 농도로 100㎕ 씩 세포에 첨가하여 4시간동안 37℃, 5% CO2에서 배양하였다. 배양액을 흡입하여 제거한 다음 DMSO(dimethyl sulfoxide) 200㎕를 첨가하고 쉐이커(shaker)에서 10분간 흔들어 준 후 엘라이저 리더(ELISA reader)로 540㎚에서 흡광도를 측정하였다.RAW 264.7 cells were aliquoted in a 96-well plate at 1×10 4 cells per well and cultured for 24 hours, followed by treatment with the extract of Example 1 at concentrations of 10, 50 and 100 μg/ml. and incubated for 48 hours. The culture solution was removed by suction and washed once with PBS, and 100 μl of MTT solution was added to the cells at a concentration of 0.5 mg/ml, and incubated at 37° C., 5% CO 2 for 4 hours. After the culture solution was removed by suction, 200 μl of dimethyl sulfoxide (DMSO) was added thereto, shaken in a shaker for 10 minutes, and absorbance was measured at 540 nm with an ELISA reader.
(3) 실험 결과(3) Experimental results
도 1에서 보듯이, 본 발명의 대혈등 추출물이 10, 50 및 100 ㎍/㎖ 농도에서 세포독성이 낮게 나타났다.As shown in FIG. 1 , the cytotoxicity was low at 10, 50 and 100 μg/ml concentrations of the extract of the present invention.
[실험예 2 : 대혈등 추출물의 항염증 활성평가][Experimental Example 2: Evaluation of anti-inflammatory activity of extracts such as Great Blood]
본 실험예에서는 대혈등 추출물의 산화질소 분비 억제에 따른 항염증 활성효과를 확인하고자 하였다.In this experimental example, it was attempted to confirm the anti-inflammatory activity of the extract from nitric oxide by inhibiting nitric oxide secretion.
(1) 대식세포주인 RAW 264.7 배양(1) Macrophage cell line RAW 264.7 culture
쥐의 대식세포주인 RAW 264.7 세포는 10% 비활성화 소태아혈청(inactivated fetal bovine serum, GIBCO)과 1% 페니실린·스트렙토마이신(penicillin·streptomycin)이 포함된 DMEM(Dul-becco's Modified Eagle's Medicum)을 배양액으로 하여 37℃에서 5% CO2 조건으로 배양하였다.RAW 264.7 cells, a mouse macrophage cell line, were treated with DMEM (Dul-becco's Modified Eagle's Medicum) containing 10% inactivated fetal bovine serum (GIBCO) and 1% penicillin streptomycin as a culture medium. and incubated at 37° C. under 5% CO 2 conditions.
(2) 산화질소 측정(2) Nitric oxide measurement
24 웰 플레이트(well plate)에 쥐의 대식세포주인 RAW 264.7을 5×105 /well 정도로 분주하고 다음날 오전에 배지를 무혈청배양액(serum free media)으로 교체한 후 약 8시간 절식(starvation)시켰다. 배양 미디아(media)는 흡입한 후 새로운 무혈청배양액(fresh serum free media)을 500㎕/well을 넣고 상기 실시예 1의 대혈등 추출물을 농도별로 가한 후 LPS 스톡 솔루션(stock solution) (100㎎/㎖)을 2.5㎕/well 처리해주고 16시간 배양하였다. 미디아(media) 상층액을 96 웰 플레이트(well plate)에 100㎕를 옮기고 동량의 그리스 시약(Griess reagent)을 100㎕ 가하고 30분간 상온에서 배양한 다음 발색의 정도를 마이크로플레이트 리더(microplate reader)의 540㎚에서 흡광도를 측정하였다.In a 24-well plate, RAW 264.7, a rat macrophage cell line, was aliquoted to about 5 × 10 5 /well, and the medium was replaced with serum free media the next morning, followed by starvation for about 8 hours. . After inhalation of the culture media, 500 μl/well of fresh serum-free media was added, and the extract of Example 1 was added by concentration, followed by LPS stock solution (100 mg/well). ㎖) was treated with 2.5 μl/well and incubated for 16 hours.
(3) 실험 결과(3) Experimental results
도 2에서 보듯이, 본 발명의 대혈등 추출물은 LPS에 의해 유도된 산화질소 NO(nitric oxide) 분비를 현저하게 억제하여 항염증 활성 효과가 우수한 점을 확인하였다.As shown in Figure 2, the extract of the present invention was confirmed that the excellent anti-inflammatory activity by significantly inhibiting the nitric oxide (NO) secretion induced by LPS.
[실험예 3 : 대혈등 추출물의 IgE 분비억제 효과 확인] [Experimental Example 3: Confirmation of IgE secretion inhibitory effect of extracts such as Daehyeol, etc.]
본 실험예에서는 대혈등 추출물의 아토피 개선 효과를 확인하고자 하였다. 아토피에 있어서 가장 큰 지표 타겟으로 알려진 물질은 면역글로불린 E(immunoglobulin E,IgE)이므로, 대혈등 추출물의 IgE의 분비 억제효과를 확인하였다. 여러 가지 항체 아이소타입(isotype) 중에서도 특별히 IgE를 많이 분비하는 사람에서 유래된 B세포주이다. B 세포가 분화가 되어 플라스마 세포가 되면 기본적으로 여러 가지 면역글로불린(immunoglobulin) 중에서 IgM을 분비하게 되고 클래스 스위칭 반응(class switching reaction)에 의해서 여러 가지 아이소타입(isotype)으로 전환된다고 알려져 있다. 이러한 아이소타입 결정에 있어서, T 세포에서 분비되는 다양한 사이토카인(cytokine)이 중요한 역할을 하며 각각의 환경에 많이 존재하는 사이토카인에 의해 IgA, IgE, IgE 등의 다양한 아이소타입으로 변화된다고 알려져 있다. 이 중에서 IgE로의 변환에 있어서는 지질다당류(polysaccharide, LPS)/ 안티-CD40 및 인터루킨-4(interleukin-4, IL-4)에 의한 자극이 필요하다는 것이 알려져 있으므로, B 세포가 IgE를 분비시키는 환경을 조성하기 위하여, B 세포의 배양시 LPS와 IL-4을 배양액에 첨가하였다.In this experimental example, it was attempted to confirm the atopy improvement effect of the extract of daehyeol, etc. Since the substance known as the largest indicator target for atopy is immunoglobulin E (IgE), the IgE secretion inhibitory effect of the extract from the Great Bloodworm was confirmed. Among various antibody isotypes, it is a B cell line derived from a person that secretes a lot of IgE. It is known that when B cells are differentiated into plasma cells, IgM is basically secreted among various immunoglobulins and converted into various isotypes by a class switching reaction. In determining such isotypes, it is known that various cytokines secreted from T cells play an important role and are changed into various isotypes such as IgA, IgE, and IgE by cytokines present in each environment. Among them, it is known that stimulation by lipopolysaccharide (LPS)/anti-CD40 and interleukin-4 (IL-4) is required for conversion to IgE, so the environment in which B cells secrete IgE is known. For composition, LPS and IL-4 were added to the culture medium when B cells were cultured.
(1) B 세포주 배양(1) B cell line culture
사람의 다발성골수종세포(multiple myeloma cells)인 U266B1를 RPMI 1640 기본 배지에 10% FBS, 1mM 피브루산나트륨(sodium pyruvate), 2mML-글루타민(glutamine), 100U 페니실린(penicillin) 그리고 50mg/㎖ 스트렙토마이신(streptomycin)이 첨가되어 있는 B세포 배지에서 37℃, 5% CO2의 배양 조건에서 배양하였다. Human multiple myeloma cells (U266B1) were prepared in RPMI 1640 basal medium with 10% FBS, 1 mM sodium pyruvate, 2 mML-glutamine, 100 U penicillin, and 50 mg/mL streptomycin. (streptomycin) was added to the B-cell medium, and cultured at 37° C. and 5% CO 2 culture conditions.
(2) IgE 농도 측정(2) IgE concentration measurement
상기에서 배양한 B세포에 10㎍/㎖의 LPS와 5ng/㎖의 IL-4를 배양액에 첨가한 후, 세포를 72시간, 37℃ 배양기에서 배양하여 B세포를 자극하였다. 72시간 후, 상기 실시예 1의 대혈등 추출물을 10, 50 및 100 ㎍/㎖ 농도로 B세포에 처리한 후 3일을 배양하였다. 3일 배양 후, 세포를 수득하여 배양액에 존재하는 IgE의 농도를 엘라이자(ELISA)를 이용하여 측정하였다.After adding 10 μg/ml of LPS and 5 ng/ml of IL-4 to the cultured B cells, the cells were cultured in an incubator at 37° C. for 72 hours to stimulate the B cells. After 72 hours, the B cells of Example 1 were treated with the extract of Dae blood, etc. at a concentration of 10, 50 and 100 μg/ml, and then cultured for 3 days. After 3 days of culture, cells were obtained and the concentration of IgE present in the culture medium was measured using ELISA.
(3) 실험 결과(3) Experimental results
도 3에서 보듯이, 본 발명의 대혈등 추출물은 B세포의 IgE 분비를 현저하게 억제하였다.As shown in FIG. 3 , the extract of Daehyeol, etc. of the present invention remarkably inhibited the IgE secretion of B cells.
[실험예 4 : 대혈등 추출물의 히스타민 분비억제 효과 확인][Experimental Example 4: Confirmation of the histamine secretion inhibitory effect of the extract of Daehyeol, etc.]
본 실험예에서는 대혈등 추출물의 아토피 개선 효과를 확인하고자 하였다. 아토피의 또다른 특징은 아토피 및 알러지 환자의 비만세포(mast cell)나 호염세포(basophil)가 분비하는 히스타민 농도의 증가이다. 비만 세포의 경우 세포 표면에 IgE에 대한 강한 반응성의 수용체(high affinity receptor)를 발현하고 있어 외부의 알러젠(allergen)이 몸속으로 들어왔을 때 IgE가 여기에 결합하게 되고 이 IgE가 다시 알러젠을 붙잡기 때문에 비만 세포가 활성화되게 된다. 이때 활성화된 비만 세포는 탈과립(degranulation)에 의해 히스타민 및 염증성 매개 인자들을 분비하게 되고 아토피나 알러지 증상을 심화시킨다. 따라서 세포에 적정 농도의 혼합 추출물을 처리하여 자극을 준 후 배양액에 분비되는 히스타민의 농도를 히스타민 검출 키트(histamine assay kit)을 이용해 측정하여, 추출물의 항알러지 또는 항아토피 효과를 확인하고자 하였다. In this experimental example, it was attempted to confirm the atopy improvement effect of the extract of daehyeol, etc. Another characteristic of atopy is an increase in the concentration of histamine secreted by mast cells or basophils in atopic and allergic patients. Mast cells express high affinity receptors for IgE on the cell surface, so when an external allergen enters the body, IgE binds to it, and this IgE captures the allergen again. Mast cells are activated. At this time, the activated mast cells secrete histamine and inflammatory mediators by degranulation, and intensify atopy or allergy symptoms. Therefore, the concentration of histamine secreted into the culture medium after stimulation by treating the cells with an appropriate concentration of the mixed extract was measured using a histamine assay kit to confirm the anti-allergic or anti-atopic effect of the extract.
(1) HMC-1 세포주 배양(1) HMC-1 cell line culture
사람의 대식 세포주인 HMC-1 세포를 IMDM 기본 배지에 10% FBS와 1%의 페니실린/스트렙토마이신(penicillin/streptomycin)이 첨가된 배양액에서 37℃, 5% CO2 의 배양 조건에서 배양하였다.HMC-1 cells, a human macrophage cell line, were cultured in a culture medium containing 10% FBS and 1% penicillin/streptomycin in IMDM basal medium at 37° C., 5% CO 2 .
(2) 히스타민 분비 측정(2) histamine secretion measurement
HMC-1세포주에 상기 실시예 1의 대혈등 추출물을 10, 50 및 100 ㎍/㎖ 농도로 처리함과 동시에, 세포를 활성화시키기 위하여, 20nM의 PMA(Phorbol 12-myristate 13-acetate, sigma)와 2 mM의 아이오노마이신(ionomycin, sigma)을 24시간 처리한 후 세포 배양액에 분비된 히스타민의 양을 ELISA를 통해 확인하였다.HMC-1 cell line was treated with the extract of Example 1 at concentrations of 10, 50 and 100 μg/ml, and at the same time to activate the cells, 20 nM PMA (Phorbol 12-myristate 13-acetate, sigma) and After treatment with 2 mM of ionomycin (ionomycin, sigma) for 24 hours, the amount of histamine secreted into the cell culture was confirmed by ELISA.
(3) 실험 결과(3) Experimental results
도 4에서 보듯이, 세포배양액에 아무것도 처리하지 않은 무처리 대조군에 비하여 대혈등 추출물이 히스타민의 분비를 감소시킴을 확인하였다.As shown in FIG. 4 , it was confirmed that the extracts from Great Blood decreased the secretion of histamine compared to the untreated control group in which nothing was treated in the cell culture medium.
[실험예 5 : 대혈등 추출물의 콜라겐 생성능 확인][Experimental Example 5: Confirmation of collagen production ability of extracts such as Great Blood]
본 실험예에서는 대혈등 추출물의 콜라겐 생성능 및 피부세포 재생 효과를 확인하고자 하였다.In this experimental example, it was attempted to confirm the collagen-producing ability and skin cell regeneration effect of the extracts from Great Blood.
(1) 피부아세포(HDFn)주 배양(1) Dermablast (HDFn) strain culture
사람의 피부아세포(HDFn, human Dermal fibroblast, neonatal)는 Gibco invitrogen cell culture에서 구입하여 실험에 사용하였다. 세포는 37℃, 5% CO2에서 10% FBS혈청, 페니실린(penicillin) 100 units/ml 과 스트렙토마이신(streptomycin) 100 ㎍/ml 그리고 2%의 LSGS (Low SErum Growth Supplement)가 첨가된 M106에 배지에서 배양하였다. 세포배양용기의 세포밀도가 80% 이상일 때 계대배양(subculture)을 실시하였으며 SFM(Serum Free Media)으로 일회세척하고 트립신(trypsin)/EDTA (0.05% trypsin, 0.53 mM EDTA)처리하여 37℃에서 세포를 탈리하였다. 이를 원심분리(1,300 rpm, 4℃)하여 포들을 회수하고 1 x 105 개로 계대하여 2-3일 간격으로 배지를 교체하면서 배양하였다.Human dermal fibroblasts (HDFn, human dermal fibroblast, neonatal) were purchased from Gibco invitrogen cell culture and used in the experiment. Cells were cultured in M106 supplemented with 10% FBS serum, 100 units/ml penicillin, 100 μg/ml streptomycin and 2% LSGS (Low Serum Growth Supplement) at 37°C, 5% CO 2 . cultured in When the cell density of the cell culture vessel was 80% or more, subculture was performed, washed once with SFM (serum free media), treated with trypsin/EDTA (0.05% trypsin, 0.53 mM EDTA), and the cells were stored at 37°C. was removed. The cells were recovered by centrifugation (1,300 rpm, 4 ℃), and cultured while replacing the medium at intervals of 2-3 days by passing 1 x 10 5 cells.
(2) 콜라겐 합성능 평가(2) Collagen synthesis ability evaluation
콜라겐 합성능 평가는 콜라겐 전구체(PIP, Procollagen Type 1C-peptide)의 C-말단을 인식하는 항체 이용법을 활용하였다. 상기 실시예1의 대혈등 추출물 10, 50 및 100 ㎍/㎖ 농도의 추출물을 각각 세포에 처치하여 배양한 후 배양액을 모아서 enzymes-linked immunoassay kit (PIP-kit, Takara사)를 이용하여 콜라겐 전구체의 C-말단의 양을 측정하였다. Collagen synthesis ability was evaluated using an antibody that recognizes the C-terminus of a collagen precursor (PIP, Procollagen Type 1C-peptide). After culturing the extracts of 10, 50 and 100 μg/ml concentration of the Great Blood extract of Example 1, respectively, the culture solution was collected and collagen precursors were obtained using an enzymes-linked immunoassay kit (PIP-kit, Takara Corporation). The amount of C-terminus was determined.
(3) 실험 결과(3) Experimental results
도 5에서 보듯이, 대혈등 추출물이 콜라겐 합성 및 피부세포 재생에 우수한 효과를 갖는 점을 확인하였다.As shown in FIG. 5 , it was confirmed that the extracts from Daehyeol, etc. had excellent effects on collagen synthesis and skin cell regeneration.
Claims (4)
A cosmetic composition for skin cell regeneration, characterized in that it contains an extract such as Great Blood and has a collagen production ability.
A food composition for skin cell regeneration, characterized in that it contains an extract such as Great Blood and has a collagen production ability.
상기 대혈등 추출물은,
에탄올을 추출용매로 사용하는 것을 특징으로 하는 조성물.The method according to claim 2 or 3,
The extract, such as the great blood,
A composition characterized in that ethanol is used as an extraction solvent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190116264A KR102259003B1 (en) | 2019-09-20 | 2019-09-20 | Composition for prevention or treatment of atopic dermatitis with Sargentodoxa cuneata |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190116264A KR102259003B1 (en) | 2019-09-20 | 2019-09-20 | Composition for prevention or treatment of atopic dermatitis with Sargentodoxa cuneata |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210034379A KR20210034379A (en) | 2021-03-30 |
| KR102259003B1 true KR102259003B1 (en) | 2021-06-02 |
Family
ID=75265036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190116264A KR102259003B1 (en) | 2019-09-20 | 2019-09-20 | Composition for prevention or treatment of atopic dermatitis with Sargentodoxa cuneata |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102259003B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114467981B (en) * | 2022-01-21 | 2023-03-21 | 湖南环境生物职业技术学院 | Black tiger fruit extract with antibacterial and antiviral effects, preparation method thereof and application thereof in preparing handmade soap or cleaning agent |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007099733A (en) | 2005-10-07 | 2007-04-19 | Shiseido Co Ltd | Antioxidant and skin lotion |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240036130A (en) * | 2011-03-28 | 2024-03-19 | 마리 케이 인코포레이티드 | Topical skin care formulations comprising plant extracts |
-
2019
- 2019-09-20 KR KR1020190116264A patent/KR102259003B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007099733A (en) | 2005-10-07 | 2007-04-19 | Shiseido Co Ltd | Antioxidant and skin lotion |
Non-Patent Citations (2)
| Title |
|---|
| Journal of Medicinal Plants Research, 2015, 9(4), pp. 104-110* |
| TMR Modern Herbal Medicine, 2018, 1(4), pp. 233-240* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210034379A (en) | 2021-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101694958B1 (en) | Composition for Improving Skin Conditions Comprising Andrographis paniculata Extract or andrographolide or salts thereof | |
| KR102259003B1 (en) | Composition for prevention or treatment of atopic dermatitis with Sargentodoxa cuneata | |
| AU2014315877A1 (en) | Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating atopic dermatitis | |
| KR101705354B1 (en) | A composition comprising the alcohol extract of Botrychium ternatum for preventing or treating skin inflammation | |
| KR102514502B1 (en) | Composition for Improving for Atopic Dermatitis, Pruritis, and Inflammation Comprising Sparasis crispa, vegetable worms, and Tuber melanosporum as Active Ingredient | |
| KR101914441B1 (en) | Cosmetic compositions for improving skin moisturizing comprising fucosterol | |
| KR102204940B1 (en) | Composition for prevention or treatment of atopic dermatitis with Illicium difengpi | |
| KR101904501B1 (en) | Cosmetic compositions for improving skin wrinkles or skin elasticity comprising fucosterol | |
| KR102282256B1 (en) | Composition for preventing, improving or treating atopic dermatitis comprising Lathyrus davidii extract | |
| KR101922089B1 (en) | Cosmetic Composition for comprising longanae arillus extracts | |
| KR102120758B1 (en) | Composition for preventing, ameliorating or treating allergic disease comprising coffee extract as effective component | |
| KR102292114B1 (en) | Composition for Improving Skin Conditions Having Moisturizing, Anti-Inflammatory Caused by Fine Dust and Pore Shrinkage Property Comprising Plant Complex Extracts as Active Ingredient | |
| KR102443334B1 (en) | Composition with Anti-Inflammation, Skin Moisturizing, Pruritis Improving, and Skin Regeneration Property Comprising Complex Extract of Hibiscus Syriacus as Active Ingredient | |
| KR20160139632A (en) | Allium monanthum extracts of biological activity | |
| KR20160061601A (en) | Cosmetic composition and pharmaceutical composition containing the extract of Corchorus olitorius L, ginko and chlorella | |
| KR102418703B1 (en) | Composition for Improving for Preventing or Treating in Skin Wrinkle and Atopic Dermatitis Comprising Extract of Thymus vulgaris Fermented by Lactic Acid Bacteria as Active Ingredient | |
| KR102557358B1 (en) | Cosmetic composition comprising Anemopsis californica extract for improving elasticity of skin and wrinkle | |
| KR102650364B1 (en) | Composition for anti-oxidation, anti-inflammation, anti-atopy, anti-wrinkle and improvement of moisturizing comprising extract of Lycorisradiata | |
| KR102563733B1 (en) | Composition for wound treatment or skin regeneration containing Aloe vera flower extract as active ingredients | |
| KR20180069755A (en) | Cosmetic Composition for comprising longanae arillus extracts | |
| KR102615763B1 (en) | Composition containing small molecular weight enzyme hydrolysates of black goat extracts and effective peptide sequence | |
| KR102157755B1 (en) | Composition for anti-inflammatory or anti-atopic containing Uncarina stellulifera extracts | |
| KR102261340B1 (en) | A composition comprising extract of Prasiola japonica for preventing or treating for inflammatory skin diseases | |
| KR20230042902A (en) | Composition for improving and treating atopic dermatitis comprising Iceland moss extract as an active ingredient | |
| KR101723899B1 (en) | A pharmaceutical composition comprising extract or fraction of Gardeniae Fructus for preventing or treating osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |